The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis

Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis

September 1, 2014 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Mortality Rates Improve for Patients with Rheumatoid Arthritis
  • Allopurinol for Gout an Unlikely Contributor to Kidney Disease
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis
Explore This Issue
September 2014
Also By This Author
  • Study Finds Pedometers Reduce Fatigue in RA Patients
Patients with CVD at baseline had a nearly twofold increased risk of developing reduced kidney function.

Data from a new study by researchers at the Mayo Clinic in Rochester, Minn., show that patients with rheumatoid arthritis (RA) are more likely to develop reduced kidney function over time compared with people without RA, highlighting the need for rheumatologists to be attentive to the risk of kidney dysfunction in their RA patients.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Rheumatologists should monitor kidney function in their patients as appropriate for their age, treatments and comorbidities,” says senior author of the study, Eric L. Matteson, MD, MPH, chair, Division of Rheumatology and professor of medicine, Divisions of Rheumatology and Epidemiology, Mayo Clinic College of Medicine, Rochester, Minn., emphasizing that control of the underlying inflammatory disease is key to reducing the comorbidity of kidney dysfunction related to RA.

Although it is known that various conditions associated with RA, such as hypertension and amyloidosis, and certain drugs affect kidney function, epidemiologic data on the frequency of kidney dysfunction in patients with RA are lacking.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Study

To fill this gap, Matteson and colleagues retrospectively reviewed data on 813 patients with adult-onset RA and a comparison cohort of 813 without RA in a Minnesota county between 1980 and 2007 to compare the cumulative incidence of reduced kidney function between the two cohorts.

Patient characteristics were largely similar between the two cohorts, with 68% women, a mean age of 56 years, and 9% having reduced kidney function at baseline. The only significant difference was in smoking status, with 45% of RA patients who had never smoked compared with 54% of non-RA patients (P=0.002) who had never smoked. Patients with RA also tended toward a higher mean baseline estimated glomerular filtration rate (eGFR) compared with non-RA patients (86 vs. 83 mL/min/1.73 m2; P=0.008).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Table 1: Risk Factors Associated with Reduced Kidney Function
click for large version
Table 1: Risk Factors Associated with Reduced Kidney Function

Reduced kidney function was defined using consecutive creatinine measurements at least 90 days apart (e.g., eGFR <60 mL/min/1.73 m2 and eGFR <45 mL/min/1.73 m2 on two consecutive occasions at least 90 days apart). Other outcomes of the study that were assessed included cardiovascular disease (e.g., myocardial infarction, revascularization procedures, angina and heart failure) and death.

The study found a significantly higher 20-year cumulative incidence of reduced kidney function (measured by eGFR <60 mL/min/1.73 m2) in the RA patients compared with non-RA patients (25% vs. 20%, P=0.03). No difference between the two cohorts was found for the development of more advanced kidney disease (measured by eGFR <45 mL/min/1.73 m2) (9% vs. 10%, P=0.8).

Risk Factors

A number of risk factors were found to be significantly related to reduced kidney function, many of which were associated with cardiovascular disease (CVD) and related risk factors (see Table 1). Patients with CVD at baseline had a nearly twofold increased risk of developing reduced kidney function as measured by eGFR <60 mL/min/1.73 m2.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Research Reviews, Rheumatoid Arthritis, Safety Tagged With: antiinflammatory, drug, function, kidney, Nierengarten, patient care, Research, Rheumatoid arthritis, rheumatologist, risk, SafetyIssue: September 2014

You Might Also Like:
  • Mortality Rates Improve for Patients with Rheumatoid Arthritis
  • Allopurinol for Gout an Unlikely Contributor to Kidney Disease
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis
  • Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)